Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Participants needed: 24
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Jun 5, 2026Locations: 20
Eligibility criteria

Diagnosis of SLE at least 24 weeks prior to Screening and meet 2019 EULAR / ACR... [+13]

Active inflammatory disease other than SLE. Thyroiditis or secondary Sjogren's s... [+14]

Read more
Status: Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.

Participants needed: 37
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: May 15, 2026Locations: 3
Eligibility criteria

Documented diagnosis of RA which fulfills the 2010 American College of Rheumatol... [+12]

Active inflammatory disease other than RA within 12 months prior to screening or... [+8]

Read more
Status: Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Mar 23, 2026Locations: 11
Eligibility criteria

Diagnosis of SjD at least 24 weeks prior to Screening Visit and meet the 2016 EU... [+20]

Read more
Status: Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Jan 16, 2026Locations: 11
Eligibility criteria

Aged ≥ 18 years of age. [+9]

Diagnosis of acute promyelocytic leukemia (APL) [+30]

Read more